Sirius secures $50m to advance siRNA therapeutics for cardiometabolic disorders
The funds are also used in the enhancement of the company’s RNA delivery technologies. A corporate venture capital firm spearheaded the financing round, with participation from new investor
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.